Michael A. Sherman
Independent DirectorMr. Michael A. Sherman, also known as Mike, M.B.A. is Independent Director at Aktis Oncology, Inc. since August 2025. He was Chairman of Chimerix, Inc. since August 01, 2023 until April 21, 2025. He serves as an Independent Director at Werewolf Therapeutics, Inc. since May 2021. He serves as an independent Board Director at Tolremo Therapeutics. He serves as Director of TOLREMO therapeutics AG since March 2024. He has experience in advancing therapeutics to commercial launch and driving companies to successful operations and strategic transactions. He was Independent Director at BioSpecifics Technologies Corp. since April 9, 2020 until December 2020. he served as Chairman at Chimerix, overseeing the company's 935 million acquisition by Jazz Pharmaceuticals in 2025. Mr. Sherman had been Chief Executive Officer of Chimerix, Inc. since April 8, 2019 until August 01, 2023 and had been its President since April 2019 until August 01, 2023 and Director since April 2019. Mr. Sherman served as the Chief Executive Officer and President of Endocyte, Inc. since June 20, 2016. Mr. Sherman served as the Chief Financial Officer of Endocyte, Inc. since October 11, 2006 until February 2017 and its Chief Operating Officer since June 16, 2014 until June 20, 2016. He served as the Principal Accounting Officer of Endocyte, Inc. until May 26, 2011. Mr. Sherman served as Director of Finance at Guidant Sales Corporation from March 1997 to March 2000. While at Guidant, he served several senior management positions, including Vice President for Finance and IT, Europe, Middle East, Africa and Canada and Corporate Controller and Chief Accounting Officer. He served as a Director for Corporate Financial Planning from 1994 to March 1997. He served positions in audit, domestic and international financial planning and reporting, business development and treasury while with Lilly and served as VP Finance and Strategic Planning at Guidant LLC from May 2004 to October 2006. He was a Director of Endocyte, Inc. since June 20, 2016 until December 21, 2018. He served as a Director of Mead Johnson Nutrition Company from February 26, 2015 to June 15, 2017. Mr. Sherman serves on the Indianapolis Children’s Museum Board of Trustees from January 2012 until December 2022. He received his Master’s in Business Administration from The Amos Tuck School at Dartmouth University and Graduated as a Tuck Scholar. Mr. Sherman holds a B.A. in Economics from DePauw University.
Positions
- Company NameWerewolf Therapeutics, Inc.Stock CodeHOWLPositionIndependent Director
